secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000886163-24-000074
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q3 revenue $51.8M (+58% YoY); raises 2024 guidance to $160-165M revenue, $5.50-5.70 adj EPS
--------------------------------------------------------------------------------

- Q3 total revenues & other income $51.8M (vs $32.9M); royalties $31.7M (+33% YoY) on QARZIBA and FILSPARI growth.
- GAAP net loss from continuing ops $7.2M ($0.39 loss/sh); core adj net income $35.3M ($1.84/sh) vs $18.0M ($1.02).
- Raised 2024 guidance: revenue now $160-165M (prev $140-157M); adj EPS $5.50-5.70 (prev $5.00-5.50).
- Received $13.5M milestone upon Ohtuvayre commercial launch; cash & investments $219.6M including $63.3M in VKTX stock.
- Issued 334,325 shares under ATM at avg $104.70 for gross $35M; up to $65M remains available.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000074/0000886163-24-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000074/lgnd-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer